All In Biotech

Drug Trial Radar · NCT06256328

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

A Randomized, Multicenter, Double-blind, Phase II Study to Compare the Efficacy and Safety of the Treatment With ONO-4578 in Combination With Nivolumab, Fluoropyrimidine-based and Platinum- Based Chemotherapy (Hereinafter Referred to as Chemotherapy) With Those of the Treatment With Placebo in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 226 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

226

Actual

Start

Jan 10, 2024

Primary completion

Oct 9, 2025

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to compare and evaluate the efficacy and safety of the treatment with ONO-4578 in combination with nivolumab and chemotherapy with those of the treatment with placebo in combination with nivolumab and chemotherapy in chemotherapy-naïve participants with HER2- negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).

Conditions

  • Gastric Cancer

Interventions

  • ONO-4578Drug

    Specified dose, once daily

  • OxaliplatinDrug

    Specified dose on specified days

  • CapecitabineDrug

    Specified dose on specified days

  • S-1Drug

    Specified dose on specified days

  • NivolumabDrug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) (site investigator assessment)Time frame: up to 2years

Locations

63 sites in 3 countries. Site status is shown where the registry gives one.

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan

  • Matsuyama Red Cross Hospital

    Matsuyama, Ehime, Japan

  • NHO Shikoku Cancer Center

    Matsuyama, Ehime, Japan

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan

  • NHO Kyushu Cancer Center

    Fukuoka, Fukuoka, Japan

  • JCHO Kyushu Hospital

    Yahatanishi-ku, Kitakyusyu-shi, Fukuoka, Japan

  • Gunma Prefectural Cancer Center

    Ota-shi, Gunma, Japan

  • Hiroshima City Hiroshima Citizens Hospital

    Hiroshima, Hiroshima, Japan

  • Hyogo Cancer Center

    Akashi-shi, Hyōgo, Japan

  • JOHAS Kansai Rosai Hospital

    Amagasaki-shi, Hyōgo, Japan

  • Kobe City Hospital Organization Kobe City Medical Center General Hospital

    Kobe, Hyōgo, Japan

  • Ibaraki Prefectural Central Hospital

    Kasama-shi, Ibaraki, Japan

  • Ishikawa Prefectural Central Hospital

    Kanazawa, Ishikawa-ken, Japan

  • Iwate Medical University Hospital

    Yahaba-cho, Shiwa-gun, Iwate, Japan

  • Kagawa University Hospital

    Miki-cho, Kita-gun, Kagawa-ken, Japan

  • Kitasato University Hospital

    Sagamihara-shi, Kanagawa, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan

  • Osaki Citizen Hospital

    Osaki-shi, Miyagi, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Kurashiki Central Hospital

    Kurashiki-shi, Okayama-ken, Japan

  • Osaka International Cancer Institute

    Chuo-ku, Osaka, Japan

  • Kansai Medical University Hospital

    Hirakata-shi, Osaka, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Osaka, Japan

  • Kindai University Hospital

    Sayama-shi, Osaka, Japan

  • Osaka General Medical Center

    Sumiyoshi-ku, Osaka, Japan

  • Osaka Medical and Pharmaceutical University Hospital

    Takatsuki-shi, Osaka, Japan

  • Saitama Cancer Center

    Ina-machi, Kitaadati-gun, Saitama, Japan

  • Shizuoka Cancer Center

    Nagaizumi-cho, Sunto-gun, Shizuoka, Japan

  • Cancer Institute Hospital of JFCR

    Koto-ku, Tokyo, Japan

  • IMSUT Hospital, The Institute of Medical Science, The University of Tokyo

    Minato-Ku, Tokyo, Japan

  • Keio University Hospital

    Shinjuku-ku, Tokyo, Japan

  • Dong-A University Hospital

    Busan, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, South Korea

  • Kyungpook National University Chilgok Hospital

    Daegu, South Korea

  • Yeungnam University Hospital

    Daegu, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Inha University Hospital

    Incheon, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Kangbuk Samsung Hospital

    Seoul, South Korea

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.